



DRAWINGS


[FIG. 1A]




[FIG. 1B]




[FIG. 2A]




[FIG. 2B]




[FIG. 3]




[FIG. 4]




[FIG. 5]




[FIG. 6A]




[FIG. 6B]




[FIG. 7A]




[FIG. 7B]




[FIG. 7C]




[FIG. 7D]




[FIG. 8A]




[FIG. 8B]




[FIG. 8C]




[FIG. 8D]



[FIG. 9A]



[FIG. 9B]




[FIG. 9C]

	Group configuration	Administered material	Administered dose	Dry eye induced
G1	Uninduced group	Vehicle	-	X
G2	Non-treated group	-	-	O
G3	Excipient group	Vehicle	-	O
G4	Control group	Restasis®	0.05%	O
G5	Test material	CG-T1	50 μ M	O

[FIG. 10A]


Representative images of fluorescein-stained cornea and CFS (corneal fluorescein scores) at Day 0, 6, 11 and 16.



[FIG. 10B]

	Group configuration	Administered material	Administered dose	Dry eye induced
G1	Uninduced group	Vehicle	-	X
G2	Non-treated group	-	-	O
G3	Excipient group	Vehicle	-	O
G4	Control group	Restasis®	0.05%	O
G5	Test material	CG-T1	50 µM	O

[FIG. 10C]



The data are presented as the mean $\pm$ SD. Significantly different at $**P < 0.01$ and $***P < 0.001$ versus G2 (Dry-eye+No-treatment) by One-wayANOVA.